Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.

Autor:	Mackintosh JA; Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia., Keir G; Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia., Troy LK; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia., Holland AE; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.; Department of Physiotherapy, The Alfred Hospital, Melbourne, Victoria, Australia.; Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Victoria, Australia., Grainge C; Department of Respiratory Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia., Chambers DC; Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia., Sandford D; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.; Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.; University of Adelaide, Adelaide, South Australia, Australia., Jo HE; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia., Glaspole I; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.; Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia., Wilsher M; Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand., Goh NSL; Department of Respiratory Medicine, Austin Hospital, Melbourne, Victoria, Australia.; Institute for Breathing and Sleep, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Reynolds PN; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.; Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.; University of Adelaide, Adelaide, South Australia, Australia., Chapman S; Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia., Mutsaers SE; Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia., de Boer S; Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand., Webster S; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Moodley Y; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.; Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.; Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia., Corte TJ; Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia.
Jazyk:	angličtina
Zdroj:	Respirology (Carlton, Vic.) [Respirology] 2024 Feb; Vol. 29 (2), pp. 105-135. Date of Electronic Publication: 2024 Jan 11.
DOI:	10.1111/resp.14656
Abstrakt:	Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis. (© 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text